<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245790</url>
  </required_header>
  <id_info>
    <org_study_id>D4300C00009</org_study_id>
    <nct_id>NCT01245790</nct_id>
  </id_info>
  <brief_title>A Study of Fostamatinib in Subjects With Impaired Kidney Function</brief_title>
  <official_title>An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2 stage study to evaluate the amount of fostamatinib in the blood and urine in subjects&#xD;
      with impaired kidney (renal) function compared with healthy volunteers with normal renal&#xD;
      function. Stage 1 will include healthy subjects and subjects with end stage renal disease,&#xD;
      while Stage, 2 may include subjects with mild, moderate and/or severe renal impairment&#xD;
      dependent on the outcome of Stage 1. The study will also evaluate safety and tolerability in&#xD;
      subjects with renal impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameters</measure>
    <description>Parameters include: AUC, Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability variables of fostamatinib 150mg: Adverse events, vital signs, physical examinations, clinical laboratory tests and electrocardiograms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine PK parameters of R406 and its N-glucuronide metabolite</measure>
    <description>PK parameters including but not limited to Amount excreted (Ae) and renal clearance (CLr)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effects of differences in protein binding by assessment of unbound R406 PK</measure>
    <description>PK parameters including, but not limited to, unbound AUC and unbound Cmaxt</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects (Stage 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild renal impairment (Stage 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate renal impairment (Stage 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe renal impairment (Stage 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>End stage renal disease (Stage 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fostamatinib</intervention_name>
    <description>Oral tablets, single dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females (non child bearing potential) greater than or equal to 18 years of&#xD;
             age with suitable veins for cannulation or repeated venipuncture and with a weight of&#xD;
             at least 50 kg (110 lbs) and body mass index (BMI) between 18 and 40 kg/m2, inclusive&#xD;
&#xD;
          -  Stable renal impairment with following creatinine clearance (CLCR): Stage 1 - End&#xD;
             Stage Renal Disease (ESRD) &lt; 15 mL/min (requiring dialysis); Stage 2 - Mild renal&#xD;
             impairment ≥ 50 to &lt; 80 mL/min; Moderate renal impairment ≥ 30 to &lt;50 mL/min; and&#xD;
             severe renal impairment 15 to &lt; 30 mL/min&#xD;
&#xD;
          -  Healthy subjects with normal renal function must have good health based on medical&#xD;
             history, physical examination , echocardiogram and clinical laboratory evaluations&#xD;
             including creatinine clearance &gt;80 ml/min&quot;&#xD;
&#xD;
          -  Negative screen for Human Immunodeficiency Virus and negative results for serum&#xD;
             hepatitis B surface antigen and hepatitis C antibody&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received any medications known to chronically alter drug absorption&#xD;
             or elimination processes within 30 days of the first dose administration&#xD;
&#xD;
          -  Absolute neutrophil count less than 1600/mm3 or 1.6 x 109 L.&#xD;
&#xD;
          -  Healthy subjects only: Subjects who have received any prescribed systemic or topical&#xD;
             medication within 14 days of the first dose administration&#xD;
&#xD;
          -  Subjects with a history of multiple drug allergies or with a known allergy to the drug&#xD;
             class of fostamatinib&#xD;
&#xD;
          -  In the opinion of the Investigator, any evidence of additional severe or uncontrolled&#xD;
             systemic disease (eg, currently unstable or uncompensated hepatic, cardiovascular, or&#xD;
             respiratory disease) or laboratory finding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Layton, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Marbury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orlando Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.studyforchange.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>November 19, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>June 15, 2011</last_update_submitted>
  <last_update_submitted_qc>June 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>volunteers with renal impairment</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>fostamatinib</keyword>
  <keyword>Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

